TZD is metabolized via CYP2C9 and CYP3A4 to a quinone metabolite, which induces oxidative stress (Scheen, 2007) and lead to intrahepatic cholestasis (Ogimura et al., 2017). The gene discussed is CYP2C9; the disease is intrahepatic cholestasis.